Intermediates for making N-aryl and N-heteroarylamide and urea
申请人:Pfizer Inc.
公开号:US05362878A1
公开(公告)日:1994-11-08
Compounds of the formula ##STR1## wherein R.sup.21 and R.sup.22 are as defined in the specification which are intermediates useful in the preparation of compounds of the formula ##STR2## and the pharmaceutically acceptable salts thereof, wherein Q and R.sup.1 are as defined in the specification. The compounds of formula I are inhibitors of acyl coenzyme A: cholesterol acyltransferase (ACAT) and are useful as hypolipidemic and antiatherosclerosis agents.
Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof
申请人:Kelly Michael G.
公开号:US20100298285A1
公开(公告)日:2010-11-25
Bicycloheteroaryl compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.